Pharmafile Logo

WHO Global Clinical Platform for COVID-19

- PMLiVE

AMR Bio launches with phase 3-ready antimicrobial gel targeting surgical infections

Antimicrobial resistance contributes to nearly five million deaths each year

- PMLiVE

WHO releases new target product profiles for urgently needed antibiotics

The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, pneumonia and meningitis

- PMLiVE

Scientists uncover new drug target in fight against antimicrobial resistance

The discovery could lead to improved treatments for bacterial infections

- PMLiVE

Invivyd working with FDA towards potential Biologics License Application for COVID-19

The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive

Kostaive is designed to instruct the body to make more mRNA to boost immune response

- PMLiVE

AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

WHO urges US to ‘reconsider’ withdrawal from global health organisation

President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

- PMLiVE

WHO launches $1.5bn emergency appeal to tackle ongoing health crises

The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links